Literature DB >> 24755947

Identification of a novel nonsense mutation in the rod domain of GFAP that is associated with Alexander disease.

Tai-Seung Nam1, Jin Hee Kim2, Chi-Hsuan Chang3, Woong Yoon4, Yoon Seok Jung5, Sa-Yoon Kang6, Boo Ahn Shin7, Ming-Der Perng3, Seok-Yong Choi8, Myeong-Kyu Kim1.   

Abstract

Alexander disease (AxD) is an astrogliopathy that primarily affects the white matter of the central nervous system (CNS). AxD is caused by mutations in a gene encoding GFAP (glial fibrillary acidic protein). The GFAP mutations in AxD have been reported to act in a gain-of-function manner partly because the identified mutations generate practically full-length GFAP. We found a novel nonsense mutation (c.1000 G>T, p.(Glu312Ter); also termed p.(E312*)) within a rod domain of GFAP in a 67-year-old Korean man with a history of memory impairment and leukoencephalopathy. This mutation, GFAP p.(E312*), removes part of the 2B rod domain and the whole tail domain from the GFAP. We characterized GFAP p.(E312*) using western blotting, in vitro assembly and sedimentation assay, and transient transfection of human adrenal cortex carcinoma SW13 (Vim(+)) cells with plasmids encoding GFAP p.(E312*). The GFAP p.(E312*) protein, either alone or in combination with wild-type GFAP, elicited self-aggregation. In addition, the assembled GFAP p.(E312*) aggregated into paracrystal-like structures, and GFAP p.(E312*) elicited more GFAP aggregation than wild-type GFAP in the human adrenal cortex carcinoma SW13 (Vim(+)) cells. Our findings are the first report, to the best of our knowledge, on this novel nonsense mutation of GFAP that is associated with AxD and paracrystal formation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24755947      PMCID: PMC4266748          DOI: 10.1038/ejhg.2014.68

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  34 in total

Review 1.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

2.  Tropomyosin paracrystals formed by divalent cations.

Authors:  C Cohen; W Longley
Journal:  Science       Date:  1966-05-06       Impact factor: 47.728

3.  Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord.

Authors:  M S van der Knaap; V Ramesh; R Schiffmann; S Blaser; M Kyllerman; A Gholkar; D W Ellison; J P van der Voorn; S J M van Dooren; C Jakobs; F Barkhof; G S Salomons
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

4.  Structure and assembly properties of the intermediate filament protein vimentin: the role of its head, rod and tail domains.

Authors:  H Herrmann; M Häner; M Brettel; S A Müller; K N Goldie; B Fedtke; A Lustig; W W Franke; U Aebi
Journal:  J Mol Biol       Date:  1996-12-20       Impact factor: 5.469

5.  Alexander disease.

Authors:  Albee Messing; Michael Brenner; Mel B Feany; Maiken Nedergaard; James E Goldman
Journal:  J Neurosci       Date:  2012-04-11       Impact factor: 6.167

6.  Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients.

Authors:  Hyun-Jung Ahn; Juhee Chin; Aram Park; Byung Hwa Lee; Mee Kyung Suh; Sang Won Seo; Duk L Na
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

Review 7.  Review of Alexander disease: beyond the classical concept of leukodystrophy.

Authors:  Yukio Sawaishi
Journal:  Brain Dev       Date:  2009-04-21       Impact factor: 1.961

Review 8.  Alexander's disease: clinical, pathologic, and genetic features.

Authors:  Anne B Johnson; Michael Brenner
Journal:  J Child Neurol       Date:  2003-09       Impact factor: 1.987

9.  GFAP mutations, age at onset, and clinical subtypes in Alexander disease.

Authors:  M Prust; J Wang; H Morizono; A Messing; M Brenner; E Gordon; T Hartka; A Sokohl; R Schiffmann; H Gordish-Dressman; R Albin; H Amartino; K Brockman; A Dinopoulos; M T Dotti; D Fain; R Fernandez; J Ferreira; J Fleming; D Gill; M Griebel; H Heilstedt; P Kaplan; D Lewis; M Nakagawa; R Pedersen; A Reddy; Y Sawaishi; M Schneider; E Sherr; Y Takiyama; K Wakabayashi; J R Gorospe; A Vanderver
Journal:  Neurology       Date:  2011-09-14       Impact factor: 11.800

10.  Expression in Escherichia coli of fragments of glial fibrillary acidic protein: characterization, assembly properties and paracrystal formation.

Authors:  R A Quinlan; R D Moir; M Stewart
Journal:  J Cell Sci       Date:  1989-05       Impact factor: 5.285

View more
  6 in total

1.  Alexander Disease: A Novel Mutation in GFAP Leading to Epilepsia Partialis Continua.

Authors:  Daniel J Bonthius; Bahri Karacay
Journal:  J Child Neurol       Date:  2015-12-29       Impact factor: 1.987

2.  A new mutation in GFAP widens the spectrum of Alexander disease.

Authors:  Michael Brenner; Albee Messing
Journal:  Eur J Hum Genet       Date:  2014-06-25       Impact factor: 4.246

3.  A novel in-frame GFAP p.E138_L148del mutation in Type II Alexander disease with atypical phenotypes.

Authors:  You-Ri Kang; So-Hyun Lee; Ni-Hsuan Lin; Seung-Jin Lee; Ai-Wen Yang; Gopalakrishnan Chandrasekaran; Kyung Wook Kang; Mi Sun Jin; Myeong-Kyu Kim; Ming-Der Perng; Seok-Yong Choi; Tai-Seung Nam
Journal:  Eur J Hum Genet       Date:  2022-03-04       Impact factor: 5.351

4.  Type II (adult onset) Alexander disease in a paraplegic male with a rare D128N mutation in the GFAP gene.

Authors:  Ki-Eun Chang; Drew Pratt; Bibhuti B Mishra; Nancy Edwards; Mark Hallett; Abhik Ray-Chaudhury
Journal:  Clin Neuropathol       Date:  2015 Sep-Oct       Impact factor: 1.368

Review 5.  Identification of a novel de novo pathogenic variant in GFAP in an Iranian family with Alexander disease by whole-exome sequencing.

Authors:  Katayoun Heshmatzad; Niloofar Naderi; Tannaz Masoumi; Hamidreza Pouraliakbar; Samira Kalayinia
Journal:  Eur J Med Res       Date:  2022-09-10       Impact factor: 4.981

6.  Aggregation-prone GFAP mutation in Alexander disease validated using a zebrafish model.

Authors:  So-Hyun Lee; Tai-Seung Nam; Kun-Hee Kim; Jin Hee Kim; Woong Yoon; Suk-Hee Heo; Min Jung Kim; Boo Ahn Shin; Ming-Der Perng; Hyon E Choy; Jihoon Jo; Myeong-Kyu Kim; Seok-Yong Choi
Journal:  BMC Neurol       Date:  2017-09-07       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.